Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD79a Purified

Anti-Hu CD79a Purified

Regulatory status

RUO

Antigen

CD79a

Clone

ZL7.4

Format

Purified

Reactivity

Human

Application

ELISA, IP, FC (QC tested), IHC(P), ICC

Variant

0.1 mg

11-869-C100

In stock

154.00 USD

Variant

0.1 mg

11-869-C100

In stock

154.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody ZL7.4 interacts with extracellular domain of CD79a (Ig alpha), a 40-45 kDa subunit of B cell antigen-specific receptor (BCR) and its early developmental forms.

Workshop

HCDM listed

Application

ELISA, IP, FC (QC tested), IHC(P), ICC

Application details

Flow cytometry: Extracellular and intracellular staining; recommended dilution: 1-5 µg/ml.

Reactivity

Human

Immunogen

IgM complex isolated from Daudi cells

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

BCR alpha, Ig-alpha, MB-1, IGA

Antigen description

CD79a (Ig alpha, MB1) forms disulfide-linked heterodimer with CD79b (Ig beta). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. At the plasma cell stage, CD79a is present as an intracellular component. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

Entrez Gene ID 973

UniProt ID P11912

Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD79a (ZL7/4) purified antibody (concentration in sample 5 μg/ml, GAM APC).

Separation of lymphocytes stained anti-human CD79a (ZL7/4) purified antibody (concentration in sample 5 μg/ml, GAM APC, red-filled) from lymphocytes unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining).

General references:

Fuentes-Pananá EM, Bannish G, Karnell FG, Treml JF, Monroe JG: Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. J Immunol. 2006 Dec 1;177(11):7913-22.
PubMed

Fuentes-Pananá EM, Bannish G, van der Voort D, King LB, Monroe JG: Ig alpha/Ig beta complexes generate signals for B cell development independent of selective plasma membrane compartmentalization. J Immunol. 2005 Feb 1;174(3):1245-52.
PubMed

Fuentes-Pananá EM, Bannish G, Shah N, Monroe JG: Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol. 2004 Jul 15;173(2):1000-11.
PubMed

Pike KA, Iacampo S, Friedmann JE, Ratcliffe MJ: The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. J Immunol. 2004 Feb 15;172(4):2210-8.
PubMed

Bannish G, Fuentes-Pananá EM, Cambier JC, Pear WS, Monroe JG: Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001 Dec 3;194(11):1583-96.
PubMed

Product specific references:

Stopforth RJ, Oldham RJ, Tutt AL, Duriez P, Chan HTC, Binkowski BF, Zimprich C, Li D, Hargreaves PG, Cong M, Reddy V, Leandro MJ, Cambridge G, Lux A, Nimmerjahn F, Cragg MS: Detection of experimental and clinical immune complexes by measuring SHIP-1 recruitment to the inhibitory FcγRIIB. J Immunol. 2018 Mar 1;200(5):1937-1950.
PubMed

Bell PB, Rooney N, Bosanquet AG: CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase. Cytometry. 1999 Jun 15;38(3):102-5.
PubMed

Luger D, Yang YA, Raviv A, Weinberg D, Banerjee S, Lee MJ, Trepel J, Yang L, Wakefield LM: Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects. PLoS One. 2013 Oct 16;8(10):e76115.
PubMed

Cragg MS, Chan HT, Fox MD, Tutt A, Smith A, Oscier DG, Hamblin TJ, Glennie MJ: The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis. Blood. 2002 Nov 1;100(9):3068-76.
PubMed